Mutations in ARID1A and ARID1B, which are not included in typical myeloid panels for NGS analysis, may play a functional role and could be responsible for ATRA resistance in ZBTB16‐RARA+AML. The gene discussed is RARA; the disease is acute myeloid leukemia.